Sunitinib News and Research

RSS

Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.

Exploring Drug Repurposing For Arboviral Infections Through Cavitomix

The CavitOmiX drug discovery method, developed by the drug and enzyme discovery platform Innophore.

2 Aug 2024

Researchers determine the novel medical target of angiogenesis for ccRCC patients

Research reported that the DMDRMR/miR-378a-5p/ DAB2IP axis enhances angiogenesis and sunitinib resistance, suggesting that it could be used for patients with ccRCC.

30 May 2022

Targeted drug shows promise against brain metastases from kidney cancer

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

22 Oct 2021

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

24 Sep 2020

In-depth study of kidney tumors reveals novel markers of response to immunotherapy

Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.

9 Sep 2020